Abstract Increasing evidence suggests that inflammation contributes to the etiology and progression of schizophrenia. Molecules that initiate inflammation, such as virus-and toxin-induced cytokines, are implicated in neuronal degeneration and schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating schizophrenia. One hundred healthy controls and 95 Han Chinese patients with schizophrenia were tested in this double-blind study. Their PANSS scores, plasma interleukin (IL)-1β, tumor necrosis factor-α (TNF-α) and brain-derived neurotrophic factor (BDNF) levels were measured before and after pharmacological treatment. Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with schizophrenia than in controls, but plasma BDNF levels were significantly lower. Patients were treated with the atypical antipsychotic risperidone (Risp) only or with Risp+ dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+ DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+ DM treatment attenuated Risp-induced plasma increases in TNF-α. Patients with schizophrenia had a high level of peripheral inflammation and a low level of peripheral BDNF. Long-term Risp treatment attenuated inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+ DM was more beneficial and less toxic than Risp-only treatment.
Introduction
Schizophrenia is a complex and severe brain disorder that causes diverse disturbances in cognition, reality testing, mood, interpersonal relations, and work functions. The etiology and pathophysiology of schizophrenia are poorly understood. While the pharmacological guidelines for schizophrenia treatment are well established, treatment for schizophrenia remains less than ideal. Because many patients with schizophrenia remain symptomatic, even while fully adherent to their medication regimens, the need for greater understanding of the pathogenesis of this illness from the research on the pharmacological mechanisms of schizophrenia medications or definite biomarker is all the more urgent.
Schizophrenia has been associated with a certain degree of central nervous system dysfunction. Imaging studies suggested that ongoing neuronal atrophy accompanies schizophrenia. For example, the significantly decreased grey matter volume (Shepherd et al. 2012) , enlarged ventricles, decreased cerebral (Rimol et al. 2012) , temporal lobe volume, and thalamic anomalies (Crespo-Facorro et al. 2007; Galderisi et al. 2008; Sowell et al. 2000) had been found in patients with schizophrenia, suggesting a role of neuronal loss and brain cell dysfunction in schizophrenia. Therefore, schizophrenia might belong to a neuronal degeneration disease.
Increasing evidence suggests that abnormal peripheral and central nervous system cytokine levels in psychosis indicate that activation of the cytokine-mediated inflammatory response system may be important in the pathogenesis of neuronal degeneration and highly relevant to the symptoms and progression of schizophrenia. For example, interleukin (IL)-1β and TNF-α are proinflammatory cytokines that modulate synaptic plasticity (Pickering and O'Connor 2007; Viviani et al. 2007) and are important in the neurodegenerative processes in the brain (Barcia et al. 2005; Grunblatt et al. 2000) . In addition, IL-1β and TNF-α sustain dopaminergic neuron degeneration in the MPTP-induced parkinsonism animal model (Barcia et al. 2005; Grunblatt et al. 2000) . Overexpressed IL-1β and TNF-α mRNA is found in the peripheral blood mononuclear cells of patients with schizophrenia (Liu et al. 2010) . Moreover, serum IL-1β and IL-6 levels (Schmitt et al. 2005 ) and cerebral spinal fluid (CSF) IL-1β levels (Soderlund et al. 2009 ) are significantly higher in patients with schizophrenia than in healthy controls. These findings suggest that the activation of inflammation contribute to the neuronal damage and degeneration found in patients with schizophrenia.
Moreover, accumulating evidence also suggests that neurotrophic factors are candidate molecules involved in the pathophysiology of mental illness. For instance, functional alterations in brain-derived neurotrophic factor (BDNF) have recently been associated with the pathophysiology of schizophrenia. BDNF, a basic dimeric protein, is a member of the nerve growth factor family involved in neuronal survival, differentiation (Mizuno et al. 1994) , synaptogenesis, and maintenance (Carrasco et al. 2007; Ohira and Hayashi 2009; Peng et al. 2003) . It has to be maintained throughout life in order to preserve essential functions such as learning and memory. BDNF promotes the survival of a wide range of neuronal cells, such as the dopaminergic neurons of the substania nigra (Hyman et al. 1991) , cerebellar granule neurons (Segal et al. 1992) , motor neurons (Oppenheim et al. 1992) , and retinal ganglion cells (Johnson et al. 1986 ). BDNF's influence on dopaminergic neurons may be relevant to the pathogenesis of schizophrenia, which is suggested to be related to dopaminergic dysfunction (Hyman et al. 1991) . Because schizophrenia is a neuronal developmental disorder, the dysfunction of BDNF might reflect the severity or the neuronal dysfunction and degeneration of schizophrenia. Using animal models, Fumagalli et al. (2004) (Fumagalli et al. 2004 ) showed a reduction in BDNF expression in the prefrontal cortex and striatum and persistently altered regulation of BDNF in the brain structures in adult rats, and Lipska et al. (2001) (Lipska et al. 2001 ) also showed a decrease in BDNF expression in the hippocampus and prefrontal cortex. Thus, we hypothesized that corticostriatal and hippocampal BDNF dysregulation contribute to permanent alterations in brain function and lead to an increased susceptibility to schizophrenia-like pathology.
Taking all these findings together, the increase in cytokine levels in patients with schizophrenia might cause neuronal damage, and a decrease in BDNF levels might indicate a reduction in neurotrophic effects in patients with schizophrenia. Treating schizophrenia with medication that has both anti-inflammatory and neurotrophic effects might be therapeutically beneficial. However, for ethical reasons, we cannot directly monitor the brain cytokine and BDNF levels of human patients.
Cytokines can cross the blood-brain barrier (Simard and Rivest 2005) , and high levels of peripheral cytokines induce sustained neuronal inflammation, damage, and degeneration (Qin et al. 2007 ). In contrast, BDNF also can cross the blood-brain barrier (Pan et al. 1998) , and BDNF levels in the brain and plasma undergo similar changes during maturation and aging processes in vivo (Karege et al. 2002; Cirulli et al. 2009 ). Therefore, peripheral cytokine and BDNF levels might be important biomarkers in schizophrenia.
The current therapeutic approach to the treatment of schizophrenia focuses on its symptoms, and the most common therapy is a dopamine antagonist or combined dopamine and serotonin antagonists for positive and negative symptoms. In this study, we used the atypical antipsychotic risperidone (Risp), a dopamine and serotonin antagonist that has been long been used to treat schizophrenia. Risp significantly attenuates the interferon-γ induced production of IL-6 and TNF-α in microglial cells in vitro (Kato et al. 2007) and in lipopolysaccharide-treated mice (Sugino et al. 2009 ). We also used, as an add-on treatment, the neuroprotective agent dextromethorphan (DM), an antitussive drug with few side effects (Wang et al. 1977) . DM is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and protects dopamine neurons against inflammation-mediated damage (Liu et al. 2003; Zhang et al. 2004 ). Thus, we hypothesize that combining these two agents might be beneficial for treating schizophrenia. In addition, high doses of DM (240-480 mg) were reported to have a tendency to be abused in human (Boyer 2004) . Thus, to preclude DM abuse, we gave participants much lower doses (60 mg).
The aims of the present study were to investigate (1) changes in the plasma levels of inflammatory factors (IL-1β, TNF-α) and plasma BDNF in patients with schizophrenia, (2) whether risperidone has anti-inflammatory and neurotrophic effects, and (3) whether combining risperidone with DM produces greater anti-inflammatory and neurotrophic effects in patients with schizophrenia than does risperidone alone. We hypothesized that Risp+ DM treatment would be more efficacious that Risp-only treatment because it targets the biochemical pathology as well as the symptoms of schizophrenia.
Methods

Patient selection
We recruited 10 patients from inpatient acute psychiatric wards and 127 from outpatient psychiatric clinics based on hospitalization status. In all, 100 healthy controls and 137 Han Chinese patients with schizophrenia; age range: 20-59 years) from the Department of Psychiatry at National Cheng Kung University Hospital and the Department of Psychiatry at the National Defense Medical Center were recruited. None of the patients had comorbid psychiatric disorders (depression or anxiety) or used illicit drugs, but about 80 % smoked cigarettes; we did not control their smoking. The Chinese version of the Schedule for Affective Disorders and Schizophrenia-Lifetime (SADS-L), which has good reliability and validity (Endicott et al. 1978; Huang et al. 2004) , was used to screen all participants for psychiatric conditions and to fit DSM-IV diagnostic criteria. The following were the exclusion criteria: 1) women who were pregnant or nursing; 2) women of childbearing potential not using adequate contraception according to investigator judgment, or not willing to use contraception for the duration of the study; 3) having taken dextromethorphan or other selective cyclooxygenase 2 (Cox-2) inhibitors or other anti-inflammatory medication within 1 week before the study began; 4) any major mental illness other than schizophrenia, including alcoholism and illegal substance use disorder; 5) any clinically significant medical condition, e.g., cardiac, hepatic, and renal disease, with current evidence of poor control; 6) having undergone electroconvulsive therapy (ECT) within 4 weeks before the study began; 7) more than 3 times the upper limit of normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine levels. The healthy controls were free of major and minor mental illness. The study protocol was reviewed and approved by the National Chung Kung University and National Defense Medical Center Institutional Review Boards (IRB) for the Use of Human Research Subjects before the study began.
Study design
This was a double-blind, stratified randomized, parallelgroup, two-center clinical trial from January 2006 to December 2008 conducted by the Department of Psychiatry at National Cheng Kung University and the Department of Psychiatry at the National Defense Medical Center, Taipei. All patients were randomly assigned to add-on treatment groups (Risp+ DM 60 mg/day or Risp+ Placebo) for 11 weeks (77 days) after they had been screened for eligibility. After the screening phase, all participants were hospitalized to modulate their medication to risperidone and then to measure their psychiatric symptoms, using PANSS, and plasma cytokines again using ELISA, at weeks 0, 2, 4, 8, and 11. The pre-treatment study phase consisted of a 7-day switch-over period-simultaneous titration of openlabel risperidone or continuation of existing risperidone dose-followed by a 1 week open-label risperidone-only (1-6 mg/day) treatment period for hospitalized patients who were taking oral antipsychotic medication other than risperidone or who had been taking depot medication for an entire cycle before the study. Concomitant benzodiazepine medication (preferably up to 8 mg of lorazepam) was used for night-time sedation, agitation, or insomnia during the study.
Positive and negative syndrome scale (PANSS)
The outcome symptom measures were psychopathological changes measured by positive and negative scores on the PANSS; the original PANSS contains 4 subscales: positive, negative, aggressive, and general psychiatric symptoms (Kay et al. 1987 (Kay et al. , 1992 . In the present study, we used the 4 components as the outcome variables for PANSS.
Plasma cytokines and BDNF measurements
Ten milliliters of whole blood was drawn from the antecubital vein of all participants at visits, 0, 1, 2, 4, 6, 8, and 11 weeks. After the whole blood had been centrifuged at 3000g for 15 min at 4°C, the plasma was isolated and immediately stored at −80°C. Plasma cytokines and BDNF levels were quantified using enzyme-linked immunosorbent assays (ELISA). A cytokine kit (Quantikine Human Cytokine Kit; R&D Systems, Minneapolis, MN) and an ELISA reader (SpectraMax-M2; Molecular Devices, Molecular Devices, Sunnyvale, CA) were used to analyze plasma IL-1β, TNF-α, and BDNF levels.
Statistical analysis
Data are means ± SEM (standard error of the mean). A t-test, a one-way analysis of variance (ANOVA), and then a Newman-Keuls test were used for the statistical evaluations. Significance was set at p<0.05.
Results
We initially enrolled 147 patients with acute schizophrenia, but 42 (30.7 %) dropped out during the trial, which finally left us with 95 patients (57 men, 38 women; age: 30.37± 0.87 years old) and 100 healthy controls (55 men, 45 women; age: 31.55±0.66 years old) who completed the 11-week study. There were no differences in demographic data between the healthy controls and patients (Table 1) .
Efficacy
Patients with schizophrenia had significantly higher pretreatment levels of plasma IL-1β (1.21±0.17 vs. 0.19± 0.04 pg/ml; p<0.001) and TNF-α (2.25±0.39 vs. 1.09± 0.16 pg/ml; p<0.05) but lower levels of plasma BDNF (4.88 ± 0.47 vs. 18.32 ± 1.13 ng/ml; p < 0.001) than did healthy controls (Fig. 1) .
There was no significant difference in the dose of Risp (mean dose: 3-4 mg/day) between the Risp+ Placebo and Risp+ DM groups from the initial visit to the end of the study (data not shown). In the inflammatory factors analysis, a significant decrease in plasma IL-1β levels and percentage was found in both the Risp+ Placebo and Risp+ DM groups after 11 weeks of treatment (Fig. 2a, c) . Although plasma TNF-α levels were not significantly different between groups, they tended to be higher in the Risp+ Placebo after 11 weeks (Fig. 2b) . We then normalized the plasma TNF-α level by the pretest (week 0 as 100 %) data and found that plasma TNF-α was significantly higher (from 100 % to 143.1±20.1 %) after 11 weeks of Risp+ Placebo treatment (Fig. 2d) . After 11 weeks of treatment, plasma BDNF levels were higher in both patient groups: Risp+ Placebo (from 100 % to 182.5 %) and Risp+ DM (from 100 % to 176 %) (Fig. 3a) . There was no significant correlation of plasma IL-1β/TNF-α/BDNF levels with the PANSS scores (data not shown); however, the plasma BDNF level was significantly negatively correlated with PANSS negative syndrome scores (Fig. 3b) .
PANSS general (data not shown), positive (Fig. 4a) , and negative symptom scores (Fig. 4b) were significantly decreasing in both Risp+ Placebo and Risp+ DM groups after 11 weeks of treatment. In addition, the Risp+ DM group showed early and more positive symptom scores decreasing profile after 11 weeks of treatment than did the Risp+ Placebo group (Fig. 4a) .
Discussion
We found that plasma cytokine levels were significantly higher in patients with schizophrenia than in healthy controls, which implied the activation of an immunological response in these patients. Higher levels of cytokines in plasma and CSF have been found in different mental illness and are hypothesized to be both causal and exacerbating factors in these diseases (Hope et al. 2009; Hu et al. 2010; Soderlund et al. 2010) . Other studies have speculated that plasma cytokines may access the brain through certain carriers or a damaged blood brain barrier (Qin et al. 2007; Quan and Banks 2007) . Qin et al. (2007) reported that a systemically administered single dose of lipopolysaccharide which could not readily reach the brain induced both early (1-9 h) serum and liver TNF-α expression and long-lasting (7-30 days) brain TNF-α expression, and, subsequently, activated microglia and caused neuronal damage and degeneration; therefore, peripheral inflammation may initiate or contribute to neuroinflammation and neurodegeneration in the central nervous system (Qin et al. 2007; Simard and Rivest 2005) . Thus, although we did not find a very high level of peripheral cytokines or a significant association between cytokines and symptom scores in schizophrenia, an increase in the level of peripheral cytokines might represent a certain degree of sustained brain inflammation in schizophrenia, which, in turn, might indicate a certain degree of cytokine induced-neuronal damage.
In the present study, we found that Risp treatment reduced elevated plasma IL-1β levels in patients with schizophrenia, and this might be the major therapeutic benefit of Risp in schizophrenia. This agrees with the finding of Song et al. (2009) that 4 weeks of Risp treatment significantly reduced IL-1β serum levels in patients with schizophrenia. Moreover, in the present study, we found that Risp treatment induced a significant increase in plasma TNF-α levels, which suggested that Risp would have a toxic effect after long-term treatment. Thus, we hypothesized that adding on the DM might provide beneficial anti-inflammatory adjuvant therapy when using Risp for extended treatment. Our finding that combined Risp+ DM treatment attenuated Risp-induced TNF-α production supports that hypothesis. Moreover, we Fig. 1 The plasma (a) TNF-α, (b) IL-1β, and (c) BDNF levels of healthy controls (n0100) and patients with schizophrenia (SCZ) (n095) before treatment. *p<0.05, **p<0.01, ***p< 0.001 vs. healthy controls (t-test) Fig. 2 The plasma (a) IL-1β and (b) TNF-α levels and their change percentages (%) (c), (d) in patients with schizophrenia after 11 weeks of treatment with risperidone (Risp)+ Placebo or Risp+ add-on dextromethorphan (DM) (60 mg/day). Plasma samples were collected and analyzed at 0, 2, 4, 8, and 11 weeks. *p<0.05, **p<0.01, ***p<0.001 vs. week 0 data within same group (repeatedmeasures ANOVA with Newman-Keuls post test)
found an early and more positive decrease in schizophrenia symptoms in the Risp+ DM group than in the Risp+ Placebo group, which indicated Risp+ DM might be therapeutically more beneficial for treating schizophrenia. DM protects dopaminergic neurons against endotoxicity (Liu et al. 2003; Zhang et al. 2004; Li et al. 2005; Zhang et al. 2005 Zhang et al. , 2006 . Liu et al. (2003) and Zhang et al. (2005a) reported that DM protected dopamine neurons against inflammation-mediated damage. The mechanism of DM's neuroprotective effect is associated with inhibiting microglial activation (Liu et al. 2003) . Thus, the above evidence that DM protects dopamine neurons in inflammation-related neurodegenerative models supports the notion that add-on DM might be more therapeutically effective than atypical antipsychotics alone in schizophrenia.
Ketamine and PCP, both NMDA antagonists, exacerbate the symptoms of schizophrenia (Jentsch and Roth 1999; Hashimoto and Iyo 2002; Javitt 2007) . In our study, we used the NMDA receptor antagonist DM and found the more beneficial in schizophrenia treatment. DM at a high dose (10 mg/kg) is an NMDA receptor antagonist (Ribeiro Do Couto et al. 2004 Couto et al. , 2005 . However, in the present study, patients took 60 mg/day (about 1 mg/kg), and their plasma DM concentrations ranged from 10 to 100 ng/ml (28-280 nM) (data not shown). Because DM is a weak NMDA receptor antagonist (ED 50 : 5-50 μM) (Church et al. 1994) , DM in such low doses might be insufficient to block NMDA receptors. However, because low dose DM has an alternative mechanism of anti-inflammation and neurotrophic effects, using low-dose DM seems to be an ideal adjuvant strategy for treating schizophrenia.
In addition, we showed a significantly (73.4 %) lower plasma BDNF level in patients with schizophrenia. BDNF can cross the blood brain barrier (Pan et al. 1998) , and BDNF levels in the brain and plasma undergo similar changes during the maturation and aging processes in rats (Karege et al. 2002) and rhesus macaques (Cirulli et al. 2009 ), which suggests that plasma BDNF levels may reflect BDNF levels in the brain. Thus, a significantly lower plasma BDNF level might reflect the dysfunction of the neurotrophic system and a certain degree of neuronal degeneration in schizophrenia. Although some studies have Fig. 3 (a) The plasma BDNF change percentages (%) after 11 weeks of treatment with risperidone (Risp) + Placebo or Risp+ add-on dextromethorphan (DM) (60 mg/day). Plasma samples were collected and analyzed at 0, 2, 4, 8, and 11 weeks. *p<0.05, **p<0.01 vs. week 0 data within same group (repeated-measures ANOVA with NewmanKeuls post test) and (b) scatter plots of plasma BDNF levels with PANSS negative symptom scores in patients with schizophrenia (Pearson r0−0.233, p00.018). Linear regression and the Pearson product-moment correlation coefficient were used to analyze the correlation Fig. 4 The change percentages (%) of (a) PANSS positive symptom scores and (b) PANSS negative symptom scores in patients with schizophrenia after 11 weeks of risperidone (Risp)+ Placebo or Risp+ add-on dextromethorphan (DM) (60 mg/day) treatment. *p<0.05, **p<0.01, **p<0.001 vs. week 0 data within same group (repeated-measures ANOVA with Newman-Keuls post test) reported negative findings of BDNF expression in patients with schizophrenia- Shimizu et al. (2003) (Shimizu et al. 2003) reported unaltered levels in 40 patients, and Takahashi et al. (2000) (Takahashi et al. 2000) reported elevated levels in the anterior cingulated cortex and hippocampus in postmortem brains-our findings agreed with those of Buckley et al. (2007) and Toyooka et al. (2002) , who reported significantly lower serum BDNF levels in patients with schizophrenia (Toyooka et al. 2002; Buckley et al. 2007) . Lower BDNF mRNA levels in the prefrontal cortex and hippocampus of patients with schizophrenia have also been reported (Thompson et al. 2011) , as have lower levels of BDNF in the dorsolateral frontal cortex (Weickert et al. 2003) , anterior cingulated cortex (Iritani et al. 2003) , and hippocampus (Durany et al. 2001) .
Low plasma BDNF protein levels in humans might reflect the degree of neuronal degeneration in Alzheimer's disease (Laske et al. 2006 ). Thus, low plasma BDNF levels might be associated with the neuronal degeneration of schizophrenia, and neurotrophic medications might be beneficial in treating schizophrenia. In our study, the plasma BDNF level was significantly higher after 11 weeks of Risp+ Placebo or Risp+ DM treatment. Studies (Yoshimura et al. 2007; Rizos et al. 2008 ) have reported no increases in plasma BDNF in patients with schizophrenia treated with Risp. However, our results agreed with those of a study (Lee and Kim 2009 ) which showed that Risp treatment significantly increased plasma BDNF levels.
In conclusion, we found an increase in inflammation and a decrease in neurotrophic response in patients with schizophrenia. Medications that are both anti-inflammatory and neurotrophic might provide therapeutic benefits for treating schizophrenia. In this study, we also found that long-term treatment with the atypical antipsychotic Risp attenuated inflammatory activity and augmented BDNF levels, and that it also produced a certain degree of toxicity. Risp+ DM seemed to be more beneficial and to prevent the toxicity produced by long-term Risp-only treatment.
